Natera (NTRA) Receives a Buy from Morgan Stanley
I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Natera (NTRA) with a $355 price target. Barclays also issued a Buy rating today, while Wells Fargo maintained a Hold rating as of August 7.
Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Natera today and set a price target of $355.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Titchmarsh is a 4-star analyst with an average return of 9.1% and a 56.67% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as Charles River Labs, 10x Genomics, and Danaher.
In addition to Morgan Stanley, Natera also received a Buy from Barclays’s Luke Sergott in a report issued today. However, on August 7, Wells Fargo maintained a Hold rating on Natera (NASDAQ: NTRA).